Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.

Trial Details

NCT ID
NCT04175431
Phase
PHASE2
Sponsor
University of Washington
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Positron Emission Tomography
  • Lymphadenectomy
  • Radiation Therapy
  • Abiraterone Acetate
  • Prednisone
  • Computed Tomography
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Patient must have histologically or cytologically documented evidence of prostate adenocarcinoma
  • Patient must previously have undergone radical prostatectomy
  • Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis
  • Patient must have a prostate specific antigen (PSA) \>= 0.2 and \< 10 ng/mL. If there is only one PSA value that has risen to \>= 0.2 with this bio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →